Slide 1: Full Year Preliminary Results 2011 Management Presentation
For personal use only Full Year Preliminary Results 2011 Management Presentation August 24 2011
Slide 2: Forward looking statements
Forward looking statements CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS For personal use only This presentation, including any comments made during or following the presentation, may contain forward-looking statements that are inherently subject to risks and uncertainties, some of which cann
Slide 3: Financial Results Snapshot
Financial Results Snapshot Issued shares 280m For personal use only Current share price $7.17 Market capitalization $2,008M Results 2011 2010 Total revenue & other income 120.9M 0.8M Operating expenses R&D 15.3M 7.6M Management 11.8M 3.6M Other 1.5M 4.4M Profit / losses (before tax) 92.2M (14.8)M EP
Slide 4: Financial Results
Financial Results For personal use only Total revenue and other income 2011 2010 Revenue from continuing operations Commercialization revenue 14.6M - Interest revenue 4.7M 0.8M Other Income - Gain on revaluation of investment to fair value 86.7M - Share of losses of equity accounted associates writt
Slide 5: Major Accomplishments
Major Accomplishments For personal use only Key financial highlights of the 2011 year: Acquired 100% ownership of Angioblast and entire intellectual property for Mesenchymal Precursor Cells (MPC) Executed a strategic alliance with Cephalon Inc. for selected product commercialization Cash flow
Slide 6: Major Accomplishments (continued)
… Major Accomplishments For personal use only Key operational highlights of the 2011 year: Commenced our first Phase 3 trial, for bone marrow transplantation Expanded cardiovascular franchise to cover heart failure, heart attacks and chronic angina Completed our congestive heart failure Phase
Slide 7: Mesoblast secures its future
Mesoblast secures its future For personal use only Cephalon (Teva) strategic alliance to fund Phase 2b and 3 clinical trials for certain product regulatory approvals sales/distribution costs associated with exclusive worldwide rights to products in cardiovascular and neurologic indications, and
Slide 8: Mesoblast secures its future
Mesoblast secures its future Mesoblast cash balance of $263 million to additionally fund: For personal use only Expansion of corporate resources - senior clinical/regulatory expertise - manufacturing and regulatory expertise for global jurisdictions - new strategic business units Major new indic
Slide 9: Manufacturing strategy is central to profitability
Manufacturing strategy is central to profitability 1. State-of-the-art manufacturing plant via strategic alliance For personal use only cost neutral tax effective geographical location best of breed, cutting edge technology 2. Retain control of manufacture for all products product delineatio
Slide 10: "Off-the-shelf" product franchises driving value creation
“Off-the-shelf” product franchises driving value creation IND clearance FDA approval For personal use only Lead products Pre-clinical Phase II Phase III Bone marrow transplantation Congestive heart failure Acute myocardial infarction Chronic refractory angina Spinal fusion Intervertebral disc repair
Slide 11: Value inflexion points – near term
Value inflexion points – near term For personal use only completion of Phase 2 heart failure trial - progression to Phase 3 pivotal trial commencement of intra-coronary heart attack Phase 2 trial completion of orthopedic Phase 2 spinal fusion trials completion of disc repair Phase 2 trial
Slide 12: Leading the world in novel adult stem cell therapies
For personal use only Leading the world in novel adult stem cell therapies